Psycho-Babble Medication Thread 1117515

Shown: posts 1 to 7 of 7. This is the beginning of the thread.

 

AXS-05, a Dextromethorphan based AD, coming soon..

Posted by PeterMartin on November 21, 2021, at 11:13:04

FDA was supposed to approve AXS-05 in October, but decided they needed more information. Disappointing. It's going to be a game changer for some people, imho. It's basically a combo of Dextromethorphan (Robitussin/cough suppressant) w/ bupropion (Wellbutrin). I had a big addiction to Robitussin (pure Dextromethorphan) in the mid-00s - mainly cause it worked amazingly for my moods. The recent study results have been great, and it works on the NMDA receptor so it's novel in method.

My guess is the FDA is worried about abuse potential.....but hopefully it'll be approved soon. You definitely can't combine it w/ an MAOI (which I'm currently on), but I think it could be effective enough to try on its own down the road (at least w/ my neurochemistry).

Has anyone else been waiting on its release?


October 2021 article on the FDA's delay in approval: https://www.medscape.com/viewarticle/960747
=====

'Impressive' Results for Novel Antidepressant, So Why the FDA Delay?

October 12, 2021

A novel antidepressant (AXS-05, Axsome Therapeutics) appears to have a rapid and durable effect in patients with major depressive disorder (MDD), results of an open label, phase 3 trial, show. Yet, its new drug application (NDA) remains in limbo with the US Food and Drug Administration (FDA) for reasons that are unclear.

In the study, which included 876 patients with MDD, results showed the drug, a combination of dextromethorphan and bupropion, had a clinical response rate of 80% and a remission rate of almost 70%. In addition, functional improvements were "substantial" and AXS-05 was determined to be "generally safe and well-tolerated."

The findings were presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress.

The Study
The COMET trial was a phase 3, multicenter, US trial, in which patients with MDD were treated with AXS-05 twice daily for up to 12 months. Patients had to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 25. They could have completed a prior AXS-05 study or be newly enrolled.

Of 876 patients included in the study, 611 were newly enrolled. The mean age was 42.4 years, and 62.4% were women. Just over half (58.1%) were white, with 35.6% black, and 2.0% Asian. The mean body mass index was 31.4 kg/m2.

The mean MADRS total score at baseline was 32.7 and the Sheehan Disability Scale (SDS) score was 20.0.

Presenting efficacy data in 609 newly enrolled patients, the team showed that MADRS total scores fell sharply on starting AXS-05, by 9.1 points at week 1, 14.0 points at week 2, and 21.2 points at week 6.

By 6 months, the reduction over baseline was 23.9 points, which was maintained out to 12 months, at a mean reduction of 23.0 points.

The proportion of patients achieving a clinical response, defined as a ≥ 50% improvement in MADRS scores, was 18.8% at week 1, 39.7% at week 2, and 73.2% at week 6. There was a clinical response in 84.6% of patients at 6 months and in 82.8% at 12 months.

Clinical remission, defined as a MADRS score ≤ 10, was achieved in 8.3% of patients at week 1, rising to 21.5% at week 2, and 52.5% at week 6. At 6 months, 68.7% of patients were in clinical remission, reaching 69.0% at 12 months.

These benefits were accompanied by substantial improvements in depressive symptoms on the Clinical Global Impression of Improvement scale, with a marked or moderate improvement seen in 86.7% of patients at 6 months and 93.1% at 12 months.

Moreover, a clinical response in functioning on the SDS was achieved by 80.6% of patients at 6 months and 75.9% at 12 months.

The safety analysis of AXS-05 in the entire cohort suggested it was well-tolerated, with dizziness seen in 12.7% of patients, along with nausea in 11.9%, headache in 8.8%, dry mouth in 7.1%, and decreased appetite in 6.1%.

The rate of discontinuation due to adverse events was 8.4%, and there were no signs of psychotomimetic effects, cognitive impairment, weight gain, or increased sexual dysfunction.

Other research presented at the meeting also showed that the drug was associated with a reduction in suicidal ideation and increased rates of suicidal ideation resolution, and was also effective for treatment-resistant depression.

Results from an analysis of the ASCEND phase 2 and GEMINI phase 3 trials also suggested that AXS-05 was superior to both bupropion and placebo in achieving rapid and sustained improvements in depression symptoms.

FDA Delay
Yet despite these seemingly positive findings, the FDA appears to have issues with the agent's new drug application.

As reported by Medscape Medical News in August, the agency reviewed the NDA for AXS-05 for the treatment of MDD, but at that time the drug's manufacturer revealed that the agency had identified "deficiencies that preclude labeling discussions at this time."

With the latest results presented at ECNP 2021, Medscape Medical News asked Axsome about the status of the NDA and whether there had been any further discussions and/or movement with the FDA.

Instead of a direct reply from the drug company, Medscape Medical News was directed to a statement released by Axsome in August announcing that the FDA had informed the company that its NDA review "would not be completed by the Prescription Drug User Fee Act target action date of August 22, 2021."

"The FDA did not request additional information from the Company, and the review of the application is ongoing," the statement said. Axsome did not respond to further questions.

"Impressive" Remission Rate
Commenting on the research for Medscape Medical News, Marin Jukic, PhD, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, who was not involved in the research, said AXS-05 "looks promising in relation to the efficacy and tolerability results" with a remission rate that is "truly impressive."

However, Jukic cautioned that it was an open-label trial and therefore had no placebo or active comparator arms.

He noted that it would be "interesting to compare the efficacy with placebo and escitalopram, for example, to evaluate the potential for the benefits and efficacy better."

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by PeterMartin on November 21, 2021, at 11:20:40

In reply to AXS-05, a Dextromethorphan based AD, coming soon.., posted by PeterMartin on November 21, 2021, at 11:13:04

Looks like you can "do it yourself" if you have an open-minded pdoc. I wasn't aware the dextromethorphan came in pill form:

https://old.reddit.com/r/Psychiatry/comments/mjahx0/diy_bupropriondextrometrophan/

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by undopaminergic on November 21, 2021, at 13:57:47

In reply to AXS-05, a Dextromethorphan based AD, coming soon.., posted by PeterMartin on November 21, 2021, at 11:13:04

> FDA was supposed to approve AXS-05 in October, but decided they needed more information. Disappointing. It's going to be a game changer for some people, imho. It's basically a combo of Dextromethorphan (Robitussin/cough suppressant) w/ bupropion (Wellbutrin). I had a big addiction to Robitussin (pure Dextromethorphan) in the mid-00s - mainly cause it worked amazingly for my moods.
>

It worked for me too once. I was unable to repeat the experience.

> The recent study results have been great, and it works on the NMDA receptor so it's novel in method.
>

Not all that novel if you consider ketamine. It is also a serotonin reuptake inhibitor -- that's why you can't take it with MAOIs.

> Has anyone else been waiting on its release?

It's not very exciting considering both bupropion and dextromethorphan are already clinically available.

-undopaminergic

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by rjlockhart37 on November 21, 2021, at 20:43:17

In reply to Re: AXS-05, a Dextromethorphan based AD, coming soon.., posted by undopaminergic on November 21, 2021, at 13:57:47

i've taken dextromethorphan before, at high doses too....it had a stimmulating effect, and small antidepressant feeling. I reerember driving through a fair, with ferris wheels and rides, everything was so vibrant and lit up while i was taking it, all the lights seemed more glowy feeling. It's a serotonin reuptake inhibitor, but after i while i just didnt geet into detromethorphan, it kinda ... made feel wierd, and plus ontop of Prozac, lots of serotonin, i'm not into it, but yes it does have antidepressant effects, with buproion, it would be stimulating because that's a double norepinephrine reptake inhibtors

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by PeterMartin on November 21, 2021, at 22:53:56

In reply to Re: AXS-05, a Dextromethorphan based AD, coming soon.., posted by undopaminergic on November 21, 2021, at 13:57:47


> It's not very exciting considering both bupropion and dextromethorphan are already clinically available.
>
> -undopaminergic

have you ever heard of a doctor prescribing the combo? It's exciting because it'll become something that doctors can become familiar with, see how patients respond, and help those who could be helped.

I doubt there's been a post on this forum in 2 decades where someone talked about using dextromethorphan w/ bupropion in combo in place of an AD. Based on the study results it can be both extremely effective, and provide a response much quick then typical ADs (w/in a week).

Insurance, legality, etc.

I think it's exciting.

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by undopaminergic on November 22, 2021, at 10:47:39

In reply to Re: AXS-05, a Dextromethorphan based AD, coming soon.., posted by PeterMartin on November 21, 2021, at 22:53:56

You have a point.

-undopaminergic

 

Re: AXS-05, a Dextromethorphan based AD, coming soon..

Posted by Jay2112 on November 28, 2021, at 16:14:52

In reply to Re: AXS-05, a Dextromethorphan based AD, coming soon.., posted by PeterMartin on November 21, 2021, at 22:53:56

I have used the dxm quite a bit...but the only one that worked for me was a long-acting formulation..can't recall the name. But, then they removed it from sale here in Canada. I don't know why. And it tasted quite good, compared to the other crap. I also used to use 120mg/12hr of pure extended release pseudophed with it. Similar idea. But, it was my *goto*...and oddly, I can't really tolerate SNRI's because of a massive jolt in anxiety. (And SRI's...well, they are just pathetic...but..).

Jay


This is the end of the thread.


Show another thread

URL of post in thread:


Psycho-Babble Medication | Extras | FAQ


[dr. bob] Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.